Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. MRNA
MRNA logo

MRNA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
55.020
Open
54.750
VWAP
53.87
Vol
6.33M
Mkt Cap
21.09B
Low
53.205
Amount
341.18M
EV/EBITDA(TTM)
--
Total Shares
394.94M
EV
16.94B
EV/OCF(TTM)
--
P/S(TTM)
11.20
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Show More

Events Timeline

(ET)
2026-03-09
16:30:00
Moderna Shares Rise 5.85% to $55.59
select
2026-03-09
10:00:00
Live Nation and Other Liquid Option Stocks Gain
select
2026-03-08 (ET)
2026-03-08
22:30:00
KKR Plans to Sell CoolIT Systems for Over $3B
select
2026-03-08
17:00:00
Dr. Vinay Prasad to Leave Agency at End of April
select
link
2026-03-04 (ET)
2026-03-04
16:20:00
U.S. Service Sector Expansion Boosts Stocks
select
2026-03-04
12:00:00
Markets Rise Amid Geopolitical Headlines
select
2026-03-04
10:00:00
Coinbase Gains 21.19 to $203.55
select

News

seekingalpha
8.5
03-11seekingalpha
mRNA Vaccine Stocks Rise as HHS Committee Revises Recommendations
  • Recommendation Revision: The HHS vaccines advisory committee has decided to walk back its previous threat to stop recommending mRNA vaccines, leading to a rise in stock prices for companies like Moderna and BioNTech during Wednesday's trading, indicating a restoration of market confidence in these vaccines.
  • Positive Market Reaction: With the committee's adjustment, mRNA vaccines, widely used during the pandemic, are back in focus for investors, enhancing expectations for future vaccine demand for companies like Moderna (MRNA) and BioNTech (BNTX).
  • Safety Controversies: Despite the positive signals from the committee's decision, some ACIP members have raised concerns about the potential harm of DNA elements in the vaccines, which could affect public acceptance and potentially impact future sales for these companies.
  • Financial Outlook: BioNTech has outlined a revenue target of €2 billion to €2.3 billion for 2026, and despite facing leadership transitions and competitive pressures, the company continues to advance its late-stage oncology pipeline, demonstrating confidence in future growth.
Benzinga
4.5
03-10Benzinga
BioNTech's Strategic Shift and Clinical Progress
  • Executive Transition: Co-founders Ugur Sahin and Özlem Türeci plan to lead a new venture by the end of 2026, prompting BioNTech's Supervisory Board to initiate a search for successors, which may impact the company's strategic direction and market confidence.
  • Clinical Trial Progress: BioNTech expects to have 15 ongoing Phase 3 clinical trials by the end of 2026, covering major cancer types, with the resulting data informing regulatory and launch plans, potentially enhancing the company's competitiveness in oncology.
  • Stock Performance: BioNTech's shares have decreased by 3.03% over the past 12 months, currently trading at $87.60, which is 18% below its 100-day simple moving average, reflecting a bearish market sentiment that could affect investor confidence.
  • Market Momentum Analysis: With a Benzinga Edge score of 19.82 indicating weak momentum, BioNTech's stock is underperforming the broader market, although the strategic pivot may present future growth opportunities, current market sentiment remains negative.
Barron's
9.5
03-10Barron's
BioNTech Announces Earnings, But That's Not the Reason for the 17% Drop in Stock Price.
  • Quarterly Loss: BioNTech reported a significant quarterly loss, indicating challenges in its operations.
  • Leadership Changes: The company announced the departure of its co-founders, marking a significant shift in its leadership structure.
Benzinga
5.0
03-09Benzinga
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
  • Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, confirmed his departure in April, prompting market interest, particularly as Moderna's stock rises due to his controversial drug review decisions.
  • Positive Market Reaction: Analyst from William Blair noted that investors are optimistic about Prasad's exit, believing it will benefit regulatory approvals for rare disease drugs, especially those utilizing single-arm studies and external controls.
  • Potential Gains for Moderna: With Prasad's departure, Moderna's mRNA-1010 vaccine could qualify for full approval in adults aged 65 and older, potentially sparing the company from conducting an additional costly vaccine efficacy study.
  • Stock Price Increases: Following the news of Prasad's resignation, stocks of Solid Biosciences and Capricor Therapeutics rose by 12.15% and 9.07%, respectively, indicating increased market confidence in rare disease treatments.
CNBC
4.5
03-09CNBC
Surge in Oil Prices Triggers Market Turmoil
  • Oil Price Surge: U.S. crude futures have surged above $100 per barrel for the first time since mid-2022, driven by Iran's threats to close the Strait of Hormuz, with a staggering 35.6% increase last week marking the largest weekly gain in futures history, which has directly impacted the stock market, leading to the Dow's worst week in nearly a year.
  • Economic Pressure Intensifies: The rising oil prices have prompted Democrats to frame the conflict as a catalyst for increased living costs, potentially affecting the upcoming midterm elections negatively, while Republicans hope for a swift resolution to avoid economic fallout, highlighting the intersection of politics and economics.
  • FDA Leadership Change: Vinay Prasad, the FDA's vaccine chief, announced his resignation effective at the end of April following widespread criticism of his decisions from the biotech and pharmaceutical sectors, illustrating the challenges and pressures regulatory bodies face in managing public health crises.
  • Changing Canadian Consumption Trends: Canadians continue to boycott U.S. goods, with data indicating a shift towards domestic brands and increased local tourism spending, a trend that could significantly impact Canada's GDP and inflation rates in the long term.
Benzinga
8.5
03-09Benzinga
uniQure Shares Surge Following FDA Official's Departure
  • Significant Stock Surge: uniQure's shares surged 31.39% to $18.75 in premarket trading following the announcement of FDA's biologics division head Vinay Prasad's resignation, extending a 33.99% increase from Friday, indicating strong market optimism about the company's future prospects.
  • Regulatory Decision Controversy: During Prasad's tenure, he faced criticism for the FDA's rejection of uniQure's Huntington's disease gene therapy application, as the agency recommended a prospective randomized controlled study, adding regulatory uncertainty that could impact uniQure's market outlook.
  • Clinical Trial Challenges: The FDA previously indicated that uniQure could pursue accelerated approval without a placebo control due to difficulties in enrolling Huntington's disease patients, reflecting regulatory flexibility for rare diseases, yet this has sparked ongoing debates about clinical trial design.
  • Strong Market Reaction: Following the news of Prasad's departure, uniQure's shares reportedly jumped as much as 70% in after-hours trading, reflecting investor expectations for a potential easing of tensions between the company and the FDA, which could pave the way for future product approvals.
Wall Street analysts forecast MRNA stock price to rise
20 Analyst Rating
Wall Street analysts forecast MRNA stock price to rise
1 Buy
16 Hold
3 Sell
Hold
Current: 0.000
sliders
Low
17.00
Averages
32.47
High
63.00
Current: 0.000
sliders
Low
17.00
Averages
32.47
High
63.00
BofA
Underperform
maintain
$31
AI Analysis
2026-03-04
Reason
BofA
Price Target
$31
AI Analysis
2026-03-04
maintain
Underperform
Reason
BofA contends that Moderna's (MRNA) settlement with Arbutus (ABUS) and Genevant (ROIV) takes "a meaningful chunk of the litigation overhang off the table," but adds that the agreement is "also not the walk-away outcome we expect some bulls were hoping for." The structure leaves "a contingent tail" as Moderna could owe an additional payment of up to $1.3B if the Federal Circuit ultimately affirms liability, notes the analyst, who reiterates an Underperform rating and $31 price target on Moderna shares.
Citi
Geoff Meacham
Neutral
maintain
$41
2026-03-04
Reason
Citi
Geoff Meacham
Price Target
$41
2026-03-04
maintain
Neutral
Reason
Citi analyst Geoff Meacham views Moderna's $2.3B settlement with Arbutus as not the best-case scenario of an outright win but better than feared. The news is likely to come as a relief to many investors, the analyst tells investors in a research note. Citi thinks the settlement removes an overhang for the stock and keeps a Neutral rating on Moderna with a $41 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MRNA
Unlock Now

Valuation Metrics

The current forward P/E ratio for Moderna Inc (MRNA.O) is -3.67, compared to its 5-year average forward P/E of -2.12. For a more detailed relative valuation and DCF analysis to assess Moderna Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.12
Current PE
-3.67
Overvalued PE
11.36
Undervalued PE
-15.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.26
Current EV/EBITDA
-2.40
Overvalued EV/EBITDA
7.55
Undervalued EV/EBITDA
-12.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
6.34
Current PS
6.29
Overvalued PS
9.06
Undervalued PS
3.61

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what about for short term profit
Intellectia · 11 candidates
Price: $5.00 - $100.00List Exchange: XNYS, XNASMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $8.00Is Index Component: GSPC, NDXMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
DOW logo
DOW
Dow Inc
26.96B
LYB logo
LYB
LyondellBasell Industries NV
23.95B
OXY logo
OXY
Occidental Petroleum Corp
57.61B
CZR logo
CZR
Caesars Entertainment Inc
5.78B
EQT logo
EQT
EQT Corp
40.39B
EW logo
EW
Edwards Lifesciences Corp
49.14B
stocks on a uptrend
Intellectia · 15 candidates
Market Cap: >= 5.00BList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Quarter Price Change Pct: >= $60.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
IBRX logo
IBRX
Immunitybio Inc
9.25B
AAOI logo
AAOI
Applied Optoelectronics Inc
7.50B
AZN logo
AZN
AstraZeneca PLC
312.56B
MRNA logo
MRNA
Moderna Inc
22.83B
VICR logo
VICR
Vicor Corp
9.22B
ENLT logo
ENLT
Enlight Renewable Energy Ltd
10.27B
What is the number one earner today?
Intellectia · 24 candidates
Market Cap: >= 10.00BPrice: >= $5.00Volume: >= 2,000,000Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
COIN logo
COIN
Coinbase Global Inc
48.16B
MSTR logo
MSTR
Strategy Inc
44.28B
IREN logo
IREN
IREN Ltd
12.89B
ASTS logo
ASTS
AST SpaceMobile Inc
35.41B
NBIS logo
NBIS
Nebius Group NV
21.96B
MRNA logo
MRNA
Moderna Inc
19.68B
stock fot today buy and sell
Intellectia · 1185 candidates
Market Cap: >= 5.00BRegion: USRelative Vol: >= 2List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceBelowMA20Week Price Change Pct: $-12.00 - $12.00Monthly Average Dollar Volume: >= 1,500,000
Ticker
Name
Market Cap$
top bottom
PAAS logo
PAAS
Pan American Silver Corp
27.50B
VIAV logo
VIAV
Viavi Solutions Inc
6.33B
XP logo
XP
XP Inc
11.25B
HSIC logo
HSIC
Henry Schein Inc
9.49B
WULF logo
WULF
Terawulf Inc
6.56B
SSL logo
SSL
Sasol Ltd
5.59B
bullish stocks this week
Intellectia · 56 candidates
Market Cap: >= 4.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
MASI logo
MASI
Masimo Corp
9.43B
IBRX logo
IBRX
Immunitybio Inc
8.41B
ONDS logo
ONDS
Ondas Inc
4.98B
MRNA logo
MRNA
Moderna Inc
18.21B
ELF logo
ELF
elf Beauty Inc
5.20B
KTOS logo
KTOS
Kratos Defense and Security Solutions Inc
17.84B
whats the next stock to watch for swing
Intellectia · 19 candidates
Rsi Category: moderateBeta: HighRiskList Exchange: XNASMoving Average Relationship: PriceAboveMA200Is Index Component: NDXMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.21T
TSLA logo
TSLA
Tesla Inc
1.52T
MU logo
MU
Micron Technology Inc
413.22B
AMZN logo
AMZN
Amazon.com Inc
2.50T
AMD logo
AMD
Advanced Micro Devices Inc
327.97B
AVGO logo
AVGO
Broadcom Inc
1.42T
which stocks have unusual options activity
Intellectia · 9 candidates
Market Cap: >= 500.00MPrice: $5.00 - $500.00List Exchange: XNYS, XNAS, XASEIs Optionable: TrueOption Unusual Activity: TrueMonthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
ASTS logo
ASTS
AST SpaceMobile Inc
38.93B
MRNA logo
MRNA
Moderna Inc
18.33B
UNH logo
UNH
UnitedHealth Group Inc
316.50B
COIN logo
COIN
Coinbase Global Inc
57.92B
BEN logo
BEN
Franklin Resources Inc
13.32B
FUN logo
FUN
Six Flags Entertainment Corp
1.76B
WHAT IS A GOOD STOCK FOR THE WEEKEND
Intellectia · 621 candidates
Market Cap: >= 5.00BAnalyst Consensus: Strong Buy, Moderate Buy, HoldList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $2.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
IBRX logo
IBRX
Immunitybio Inc
6.38B
FTAI logo
FTAI
FTAI Aviation Ltd
29.96B
UUUU logo
UUUU
Energy Fuels Inc
6.05B
BE logo
BE
Bloom Energy Corp
34.27B
MRNA logo
MRNA
Moderna Inc
18.33B
APLD logo
APLD
Applied Digital Corp
10.66B
any optionable ideas for today?
Intellectia · 8 candidates
Is Optionable: TrueOption Unusual Activity: TrueMonthly Average Dollar Volume: >= 1,000,000News Driver: Positive, Negative
Ticker
Name
Market Cap$
top bottom
MRNA logo
MRNA
Moderna Inc
20.26B
META logo
META
Meta Platforms Inc
1.63T
ASTS logo
ASTS
AST SpaceMobile Inc
42.75B
UNH logo
UNH
UnitedHealth Group Inc
321.09B
CRCL logo
CRCL
Circle Internet Group Inc
16.80B
COIN logo
COIN
Coinbase Global Inc
60.17B
any stock day trade tomorrow
Intellectia · 95 candidates
Price: $5.00 - $80.00Market Cap Category: large, midPrice Change Pct: $3.00 - $15.00Beta: HighRiskMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
IBRX logo
IBRX
Immunitybio Inc
7.23B
BBAI logo
BBAI
BigBear.ai Holdings Inc
2.59B
NU logo
NU
Nu Holdings Ltd
87.22B
ACHR logo
ACHR
Archer Aviation Inc
6.60B
SNAP logo
SNAP
Snap Inc
13.17B
QBTS logo
QBTS
D-Wave Quantum Inc
10.14B

Whales Holding MRNA

T
Two Sigma Investments, LP
Holding
MRNA
+8.74%
3M Return
H
Himension Capital (Singapore) Pte Ltd
Holding
MRNA
+5.24%
3M Return
Y
Y-Intercept (Hong Kong) Limited
Holding
MRNA
+2.39%
3M Return
T
Tang Capital Management, LLC
Holding
MRNA
+0.17%
3M Return
L
Leonteq AG
Holding
MRNA
-1.35%
3M Return
B
Banque Pictet & Cie SA
Holding
MRNA
-1.45%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Moderna Inc (MRNA) stock price today?

The current price of MRNA is 53.39 USD — it has decreased -4.61

What is Moderna Inc (MRNA)'s business?

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

What is the price predicton of MRNA Stock?

Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is32.47 USD with a low forecast of 17.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Moderna Inc (MRNA)'s revenue for the last quarter?

Moderna Inc revenue for the last quarter amounts to 678.00M USD, decreased -29.81

What is Moderna Inc (MRNA)'s earnings per share (EPS) for the last quarter?

Moderna Inc. EPS for the last quarter amounts to -2.11 USD, decreased -26.99

How many employees does Moderna Inc (MRNA). have?

Moderna Inc (MRNA) has 4700 emplpoyees as of March 13 2026.

What is Moderna Inc (MRNA) market cap?

Today MRNA has the market capitalization of 21.09B USD.